iPSC Derived Cardiomyocytes and 3D Tissue Contractility Analysis | NEXEL

NEXEL Co., Ltd. is committed to becoming a world-class biotech company. Its aim is to develop innovative new therapies to help patients and provide tools for researchers to boost their projects. Thus, they will create value for the investors, fellow researchers, and the world to make a better place.

NEXEL is a world leader in iPSC (induced pluripotent stem cell) technology as the first Korean company to license iPS technology and setting a new paradigm in the in vitro toxicity field through successful commercialization of iPS derived cells which mimic actual human functionality. Furthermore, they are investing its expertise into the discovery and development of new drug candidates based on proteins and peptides derivations from stem cell technology.

NEXEL iPSC Derived Cardiomyocytes 

NEXEL strives to provide high quality human cardiomyocytes from human induced pluripotent stem (iPS) cells using optimized proprietary protocols. The cardiosight-S is a highly pure and electrophysiologically active population of cells, suitable for all types of experiments in the field of cardiomyocytes. Its priority is to ensure researchers get a reliable product and accelerate the diverse projects they are working on.

Also, its human iPSC derived cardiomyocytes have been validated on multiple platforms and the quality control process has been optimized to test the exact settings in which customers use its product. Through and comprehensive testing it ensures that the cells have been tested both on the nanion cardioexcyte96 and the axion maestro MEA, making them the best choice for your MEA assay. Its certificate of analysis (CoA) contains the exact results obtained and the technical support team will work with you to provide the same experience in your lab.

NEXEL's Mantarray (3D Tissue Contractility Analysis)
Mantarray brings functional data into the earliest stages of preclinical testing of new medicine. By providing parallel analysis of 3D engineered muscle tissues with adult-like functional profiles, Mantarray enables the discovery, safety, and efficacy testing of new therapeutics.

The Mantarray system features a novel magnetic sensing technique that can detect the contraction of EMTs. These 3D engineered organoid plates enable the user to measure the contractility of 24 tissues in parallel, with high throughput and in real time. The system features user-friendly software that takes away the requirement for manual calculations of contractility, delivering contractility data at the click of a mouse. This system uses ANSI/SLAS compliant tissue casting devices that can be performed manually or via automation. MTs can be used in nearly any kind of assay, including force (contractility), calcium, and structural assays. Mantarray brings EMTs into your own lab, allowing you to use your own cells to achieve your research goals.

If you are looking for iPSC Derived Cardiomyocytes and 3D Tissue Contractility Analysis, you can find it at NEXEL.

Click here to contact NEXEL.

View more: NEXEL iPSC Derived Cardiomyocytes and 3D Tissue Contractility Analysis

Korea

NEXEL Co., Ltd. is committed to becoming a world-class biotech company.

This release was published on openPR.